Moderate Restriction of Macrophage-Tropic Human Immunodeficiency Virus Type 1 by SAMHD1 in Monocyte-Derived Macrophages

Kahoru Taya, Emi E. Nakayama, Tatsuo Shioda*

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan

Abstract

Macrophage-tropic human immunodeficiency virus type 1 (HIV-1) strains are able to grow to high titers in human monocyte-derived macrophages. However, it was recently reported that cellular protein SAMHD1 restricts HIV-1 replication in human cells of the myeloid lineage, including monocyte-derived macrophages. Here we show that degradation of SAMHD1 in monocyte-derived macrophages was associated with moderately enhanced growth of the macrophage-tropic HIV-1 strain. SAMHD1 degradation was induced by treating target macrophages with vesicular stomatitis virus glycoprotein-pseudotyped human immunodeficiency virus type 2 (HIV-2) particles containing viral protein X. For undifferentiated monocytes, HIV-2 particle treatment allowed undifferentiated monocytes to be fully permissive for productive infection by the macrophage-tropic HIV-1 strain. In contrast, untreated monocytes were totally resistant to HIV-1 replication. These results indicated that SAMHD1 moderately restricts even a macrophage-tropic HIV-1 strain in monocyte-derived macrophages, whereas the protein potently restricts HIV-1 replication in undifferentiated monocytes.

Introduction

CD4 is the primary receptor molecule of human immunodeficiency virus type 1 (HIV-1) for viral attachment to the target cells [1]. HIV-1 thus replicates in CD4$^+$ cells such as activated human CD4$^+$ lymphocytes and macrophages [2,3]. Among different HIV-1 strains, macrophage-tropic HIV-1 strains replicate particularly well in cultured human monocyte-derived macrophages [4]. Many macrophage-tropic HIV-1 strains fail to replicate well in established human T cell lines such as Hut78 and MT4, cell lines in which laboratory-adapted T-cell line-tropic HIV-1 strains can replicate efficiently. Conversely, many laboratory-adapted T-cell line-tropic HIV-1 strains fail to replicate well in monocyte-derived macrophages [5]. Sequence variations in the HIV-1 envelope protein, especially in the third variable region, correlate with the HIV-1 cellular host range [6–9], and this observation led to the identification of the CCR5 and CXCR4 chemokine receptors as HIV-1 co-receptors for viral fusion with target cell membranes [10–16]. Macrophage-tropic HIV-1 strains utilize CCR5 as a co-receptor, and most such macrophage-tropic HIV-1 strains now have been re-designated as R5-tropic strains, although not all the R5-tropic HIV-1 strains can efficiently replicate in macrophages [17–19]. Laboratory-adapted T-cell line-tropic HIV-1 strains utilize CXCR4 as a co-receptor, and most such T-cell line-tropic HIV-1 strains now have been re-designated as X4-tropic strains, although CXCR4 expression also was observed in macrophages [20–22], cells in which X4-tropic strains cannot replicate well.

Despite the presence of the aforementioned HIV-1 strains that can replicate well in macrophages, it has been also reported that HIV-1-based lentivirus vectors composed of HIV-1 Gag and Pol proteins and vesicular stomatitis virus glycoprotein (VSV-G) showed markedly reduced efficiency for transduction of cells of myeloid lineage [23,24]. The restriction was rather strong in monocyte-derived dendritic cells and to a lesser extent in monocyte-derived macrophages [25,26]. Such a myeloid lineage-specific restriction was not observed in lentivirus vectors based on simian immunodeficiency virus isolated from macaques (SIVmac) [26], which is in the same lineage as human immunodeficiency virus type 2 (HIV-2), or in simian immunodeficiency virus isolated from sooty mangabey (SIVsm). The myeloid lineage-specific restriction of HIV-1-based lentivirus vector could also be abrogated by pretreatment of cells with SIVmac particles [27]. Members of HIV-2 and SIVsm lineage encode a non-structural viral protein X (Vpx) that is absent from HIV-1. VpX was shown to abrogate the myeloid lineage-specific restriction of HIV-1-basesd lentivirus vectors [27–29].

In 2011, SAMHD1 (a cellular protein SAM- and HD-domain-containing protein) was implicated as a target of Vpx that was responsible for abrogation of HIV-1 restriction in human cells of myeloid lineage [30,31]. Subsequently, SAMHD1 was shown to restrict HIV-1 infection in resting CD4$^+$ T cells [32]. SAMHD1 possesses deoxynucleoside triphosphate triphosphohydrolase activity; this activity reduces levels of deoxynucleoside triphosphate in cells of myeloid lineage and resting CD4$^+$ cells, thereby preventing reverse-transcription of HIV-1 RNA in these cell types

[33,34]. Vpx antagonizes SAMHD1 and induces proteolytic degradation of SAMHD1 through the CUL4A/DCAF1 E3 ubiquitin ligase complex [30].

In most of the SAMHD1 studies cited above, the efficiency of HIV-1 infection was assayed in the context of lentivirus vectors composed of HIV-1 Gag and Pol proteins packaged with VSV-G protein, along with reporter genes such as those encoding luciferase or green fluorescent protein. This distinction raises the question of whether SAMHD1 provides the same function in live HIV-1 viruses. Therefore, in the study presented here, we re-evaluated the role of SAMHD1 in HIV-1 replication in monocyte-derived macrophages in the context of a live macrophage-tropic HIV-1 strain that can replicate well in macrophages.

Results

Lack of Enhancing Effect of Macrophage-tropic HIV-1 Strain on HIV-1 Infection in Monocyte-derived Macrophages

SAMHD1 was reported to suppress infection of HIV-1-based lentivirus vectors containing VSV-G in cultured monocyte-derived macrophages [30]. On the other hand, macrophage-tropic HIV-1 strains can efficiently replicate in monocyte-derived macrophages [4]. To reconcile these potentially contradictory results, we tested the hypothesis that live macrophage-tropic HIV-1 strains can evade restriction of SAMHD1 by an unidentified mechanism. As a first step, we treated monocyte-derived macrophages with a macrophage-tropic HIV-1 strain SF162 before inoculation with VSV-G-pseudotyped lentivirus vector expressing luciferase (NL43-Luci/VSV-G). Results showed that pretreatment with SF162 failed to enhance subsequent infection by NL43-Luci/VSV-G in macrophages (Fig. 1A and 1B, left panels), whereas pretreatment with VSV-G-pseudotyped and Env-defective HIV-2 particles containing Vpx (GH123-Nhe/VSV-G) enhanced luciferase expression (Fig. 1A and 1B, left panels), as reported previously [30]. The effect of GH123-Nhe/VSV-G was more prominent in undifferentiated monocytes than in fully differentiated macrophages; a more than 200-fold increase of luciferase activity was observed by pretreatment of monocytes with GH123-Nhe/VSV-G (Fig. 1A and 1B, right panels). SF162 again failed to enhance subsequent infection by NL43-Luci/VSV-G in monocytes (Fig. 1A and 1B, right panels).

Enhancing Effect of VSV-G Pseudotyped HIV-2 Particles on Macrophage-tropic HIV-1 Strain in Monocyte-derived Macrophages

We next tested whether GH123-Nhe/VSV-G also could enhance replication of a macrophage-tropic HIV-1 strain in monocyte-derived macrophages. Fig. 2 shows the effects of GH123-Nhe/VSV-G on replication of SF162 in cultured macrophages that were differentiated from monocytes with granulocyte-macrophage colony stimulating factor (GM-CSF). SF162 replicated to titers corresponding to approximately 100 ng/ml of p24 core protein (Fig. 2A and 2B, left panels). Up to five-fold higher titers were detected in SF162-infected macrophages pretreated with GH123-Nhe/VSV-G (Fig. 2A and 2B, left panels). These results indicated that GH123-Nhe/VSV-G could enhance replication of macrophage-tropic HIV-1 in GM-CSF-differentiated macrophage cultures. In contrast, the T-cell line-tropic HIV-1 strain NL43 did not replicate at all in macrophages, regardless of the presence or absence of GH123-Nhe/VSV-G treatment (Fig. 2A and B, right panels).

Monocyte-derived macrophages differentiated with macrophage colony stimulating factor (M-CSF) are more susceptible to HIV-1 infection than those differentiated with GM-CSF [35–38]. We therefore tested whether GH123-Nhe/VSV-G could enhance SF162 replication in monocyte-derived macrophages differentiated with M-CSF. SF162 grew to titers corresponding to 200 ng/ml of p24 in donor 1 macrophages (Fig. 3A, left) and to 400 ng/ml of p24 in donor 2 macrophages (Fig. 3B, left), a level at least two-fold higher than those found in SF162-infected macrophage cultures differentiated with GM-CSF. Up to five-fold higher titers of SF162 also were detected in M-CSF-differentiated macrophage cultures pretreated with GH123-Nhe/VSV-G (Fig. 3A and 3B, left panels). These results indicated that GH123-Nhe/VSV-G could enhance replication of macrophage-tropic HIV-1 replication even in M-CSF-differentiated macrophages. The T-cell line-tropic NL43 strain again did not replicate at all in M-CSF-differentiated macrophages, regardless of the presence or absence of GH123-Nhe/VSV-G treatment (Fig. 3A and 3B, right panels).

Enhancing Effect of VSV-G-pseudotyped HIV-2 Particles on Macrophage-tropic HIV-1 Strain in Undifferentiated Monocytes

In contrast to differentiated macrophages, undifferentiated monocytes are highly resistant to HIV-1 infection, but treatment with GH123-Nhe/VSV-G greatly enhanced VSV-G-pseudotyped lentivirus vector transduction (Fig. 1A and 1B, right panels). This pattern also was observed for live SF162 infection of undifferentiated monocytes (Fig. 4 and 5). SF162 replication in monocytes was not observed until 12 days after infection, when cell morphology suggested that some of the monocytes in the culture had differentiated into macrophages. On the other hand, GH123-Nhe/VSV-G rendered cultured monocytes fully permissive for SF162 replication (Fig. 4A and 4B, left panels). Up to 50-fold higher titers of SF162 were detected in monocytes treated with GH123-Nhe/VSV-G than in untreated monocytes. Consistently, large multi-nucleated syncytia were observed 6 days after infection, but only in monocytes treated with GH123-Nhe/VSV-G (Fig. 5). These results are in good agreement with recent findings that non-stimulated CD14$^+$ cells obtained from Aicardi-Goutieres syndrome patients (who are homozygous for a nonsense mutation in the SAMHD1-encoding gene) were highly susceptible to macrophage-tropic HIV-1 infection [39]. As with GM-CSF- and M-CSF-differentiated macrophages, the T-cell line-tropic NL43 strain did not replicate at all in undifferentiated monocytes, regardless of the presence or absence of GH123-Nhe/VSV-G treatment (Fig. 4A and 4B, right panels).

Levels of SAMHD1 Expression in Monocytes and Macrophages

Vpx was reported to induce proteolytic degradation of SAMHD1. We therefore compared levels of SAMHD1 protein expression in cells treated with GH123-Nhe/VSV-G and those without treatment. As shown in Fig. 6, GH123-Nhe/VSV-G markedly reduced levels of SAMHD1 protein expression in monocytes and macrophages. Consistent with the previous observation [31], levels of SAMHD1 protein expression were apparently higher in undifferentiated monocytes than in macrophages.

We then quantitated levels of SAMHD1 mRNA expression in monocytes and macrophages. As expected, SAMHD1 mRNA levels were higher in monocytes than in macrophages (Fig. 7). There was no difference in SAMHD1 mRNA levels between cells treated with GH123-Nhe/VSV-G and those without treatment.

A

B

Figure 1. Effects of macrophage-tropic HIV-1 strain and VSV-G-pseudotyped HIV-2 particles on lentivirus vector infection. Monocytes were differentiated into macrophages for 11 days in the presence of GM-CSF. Macrophages or monocytes were treated with macrophage-tropic HIV-1 strain (SF162) or VSV-G pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G) and then infected with lentivirus vector NL43-Luci/VSV-G. Luciferase activity was measured 4 days after infection. Data are plotted as the mean ± SD of triplicate samples; presented data are representative of three independent experiments using two donors. A: Results of samples obtained from a donor 1. B: Results of samples obtained from a donor 2.
doi:10.1371/journal.pone.0090969.g001

These results confirmed that reduced SAMHD1 protein levels in cells treated with GH123-Nhe/VSV-G were caused by enhanced degradation of SAMHD1 by HIV-2 particles containing Vpx.

Phosphorylation of SAMHD1 in Monocytes and Differentiated Macrophages

It was recently reported that Cyclin A2/CDK1 phosphorylates SAMHD1 at the threonine 592 residues. Phosphorylation of the SAMHD1 threonine 592 correlates with loss of its ability to restrict HIV-1 [40–42]. We therefore analyzed the phosphorylation state of SAMHD1 in monocytes and differentiated macrophages. As shown in Fig. 8, SAMHD1 proteins in monocytes were less phosphorylated than those in GM-CSF-differentiated or M-CSF-differentiated macrophages. This result is in good agreement with those reported previously [40], and correlated well with our results that SAMHD1 restriction in monocytes was much more potent than that in differentiated macrophages (Fig. 1 and 4). Treatment with GH123-Nhe/VSV-G reduced both phosphorylated and nonphosphorylated SAMHD1 in all cells. There was no difference in the phosphorylation state of SAMHD1 between GM-CSF-differentiated and M-CSF-differentiated macrophages (Fig. 8).

Enhancing Effect of SAMHD1 siRNA on HIV-1 Infection in Monocytes and Monocyte-derived Macrophages

To confirm that the observed enhancing effect of VSV-G-pseudotyped HIV-2 particles on HIV-1 infection was due to degradation of SAMHD1 in monocytes and macrophages, we used siRNAs targeting SAMHD1 to reduce levels of SAMHD1 expression. The siRNAs targeting SAMHD1 reduced levels of SAMHD1 mRNA in both monocytes and GM-CSF-differentiated macrophages (Fig. 9A and 9B, left panels). Accordingly, increased levels of NL43-Luci/VSV-G infection were observed in monocytes (Fig. 9A and 9B, middle panels) and GM-CSF-differentiated macrophages (Fig. 9A and 9B, right panels) transfected with the siRNAs targeting SAMHD1. These results confirmed that the enhancing effect of VSV-G-pseudotyped HIV-2 particles on HIV-1 infection was due to degradation of SAMHD1.

Discussion

SAMHD1 was reported to suppress HIV-1 infection of cells of myeloid lineage, including monocyte-derived macrophages [30,31]. Nevertheless, macrophage-tropic HIV-1 strains can efficiently replicate in monocyte-derived macrophages [4,6–8].

A

B

Figure 2. Effects of VSV-G-pseudotyped HIV-2 particles on macrophage-tropic and T-cell line-tropic HIV-1 strains in GM-CSF-induced macrophages. Monocytes were differentiated into macrophages for 6 days in the presence of GM-CSF. Macrophages were treated with VSV-G pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G) and then infected with HIV-1 strain SF162 or NL43. HIV-1 replication was quantified by ELISA measurement of p24 antigen in the supernatant after infection. Data are plotted as the mean ± SD of triplicate samples; presented data are representative of three independent experiments using two donors. A: Results of samples obtained from a donor 1. B: Results of samples obtained from a donor 2.
doi:10.1371/journal.pone.0090969.g002

In the present study, we have shown that the treatment of monocyte-derived macrophages or undifferentiated monocytes with GH123-Nhe/VSV-G enhanced subsequent macrophage-tropic HIV-1 infection. GH123-Nhe/VSV-G treatment reduced levels of SAMHD1 protein expression in monocyte-derived macrophages and undifferentiated monocytes. Enhancing effects by GH123-Nhe/VSV-G were observed even in M-CSF-induced monocyte-derived macrophages, which were reported to be highly susceptible to HIV-1 infection [35–38,43]. These results indicated that SAMHD1 could moderately suppress replication of the macrophage-tropic HIV-1 strain in monocyte-derived macrophages. It is formally possible that live macrophage-tropic HIV-1 strains evade restriction of SAMHD1 by an unidentified mechanism, although we consider such a possibility unlikely.

Levels of HIV-1 restriction by SAMHD1 in monocyte-derived macrophages were rather modest, while those in undifferentiated monocytes were quite strong (Fig. 2, 3 and 4). SAMHD1 expression levels were higher in undifferentiated monocytes than in monocyte-derived macrophages (Fig. 6 and 7), showing a clear correlation between levels of SAMHD1 expression and those of restriction. Furthermore, phosphorylation of SAMHD1, which was reported to abolish HIV-1 restriction activity of SAMHD1 [40–42], was more prominent in M-CSF-induced or GM-CSF-induced macrophages than in undifferentiated monocytes (Fig. 8). When we compared M-CSF-induced and GM-CSF-induced macrophages, HIV-1 grew to higher titers in M-CSF-induced macrophages than in GM-CSF-induced macrophages. This result is in good agreement with those of the previous studies [37,43]. The levels of restriction by SAMHD1 also were slightly lower in M-CSF-induced macrophages than in GM-CSF-induced macrophages, although we failed to observe clear differences in levels of expression or phosphorylation state of SAMHD1 between M-CSF-induced and GM-CSF-induced macrophages (Fig. 6, 7, and 8). Thus, mechanisms underlying the higher sensitivity to HIV-1 infection in M-CSF-induced macrophages are not clear at present; further studies are necessary, including comparisons of CD4 and CCR5 expression levels between M-CSF-induced and GM-CSF-induced macrophages.

A

B

Figure 3. Effects of VSV-G-pseudotyped HIV-2 particles on macrophage-tropic and T-cell line-tropic HIV-1 strains in M-CSF-induced macrophages. Monocytes were differentiated into macrophages for 6 days in the presence of M-CSF. Macrophages were treated with VSV-G pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G) and then infected with HIV-1 strain SF162 or NL43. HIV-1 replication was quantified by ELISA measurement of p24 antigen in the supernatant after infection. Data are plotted as the mean ± SD of triplicate samples; presented data are representative of two independent experiments using two donors. A: Results of samples obtained from a donor 1. B: Results of samples obtained from a donor 2.
doi:10.1371/journal.pone.0090969.g003

It should be noted here that the effects of GH123-Nhe/VSV-G treatment seem to last relatively long, although we treated cells only once with GH123-Nhe/VSV-G. It is possible that the Vpx protein produced by the transduced HIV-2 genomes was incorporated into infectious SF162 progeny virions and thus facilitated replication of SF162 in the next cycle of infection. It is also possible that Env-deficient progeny HIV-2 virions were pseudotyped with fully functional SF162 envelope proteins, and thereby continued to produce Vpx that degraded SAMHD1.

Similar to monocytes and macrophages, microglial cells in the human brain are derived via the myeloid lineage and are also susceptible to HIV-1 infection [44]. HIV-1-infected microglial cells appear to play an important role in HIV-1-associated neurological disorders such as dementia and neurocognitive disorder [45]. It therefore would be interesting to investigate whether or not SAMHD1 moderately suppresses HIV-1 replication in microglial cells just as in macrophages. If SAMHD1 can suppress HIV-1 replication at least moderately in microglial cells,

artificial potentiation of SAMHD1 in microglial cells might be a novel approach to the treatment of HIV-1-associated neurological disorders.

In conclusion, we have shown that SAMHD1 moderately restricts even macrophage-tropic HIV-1 strains in monocyte-derived macrophages. SAMHD1 restriction was much more potent in undifferentiated monocytes than that in GM-CSF-differentiated or M-CSF-differentiated macrophages. Levels of expression and phosphorylation state of SAMHD1 could at least partially explain the different levels of SAMHD1 restriction between undifferentiated monocytes and differentiated macrophages.

Materials and Methods

Ethics Statement
Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors with written informed consent. Use of human

A

B

Figure 4. Effects of VSV-G-pseudotyped HIV-2 particles on macrophage-tropic and T-cell line-tropic HIV-1 strains in undifferentiated monocytes. Monocytes were treated with VSV-G pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G) and then infected with HIV-1 strain SF162 or NL43. HIV-1 replication was quantified by ELISA measurement of p24 antigen in the supernatant after infection. Data are plotted as the mean ± SD of triplicate samples obtained from a single blood donor; presented data are representative of three independent experiments using two donors. A: Results of samples obtained from a donor 1. B: Results of samples obtained from a donor 2.
doi:10.1371/journal.pone.0090969.g004

materials in this study was approved by the Research Ethics Committee of Osaka University.

Viruses

Macrophage-tropic HIV-1 strain SF162 and laboratory-adapted T-cell line-tropic HIV-1 strain NL43 were grown in CCR5-expressing MT4 cells [46] and titrated for use with the RETROtek Antigen ELISA kit (ZeptoMetrix, Buffalo, NY). VSV-G-pseudotyped lentivirus vector expressing luciferase (NL43-Luci/VSV-G) and VSV-G-pseudotyped and Env-defective HIV-2 particles containing Vpx (GH123-Nhe/VSV-G) were produced from human embryonic kidney cells (293T cells) using polyethylenimine (PEI) (molecular weight, 25,000; Polysciences, Warrington, PA). Briefly, for NL43-Luci/VSV-G virus production, 293T cells were transfected with 15 μg of pNL4-3-Luc-R-E- plasmid and 5 μg of VSV-G-encoding plasmid; for GH123-Nhe/VSV-G virus production, 293T cells were transfected with 15 μg of GH123-Nhe and 5 μg of VSV-G-encoding plasmid. The GH123-Nhe plasmid

was generated by blunting the *Nhe*I site in the HIV-2 GH123 plasmid, thereby introducing a frame-shift mutation in its *env* gene. For transfected cells, medium was replaced 6 h after transfection, and viruses were harvested 48 h later. Viral titers were measured with the RETROtek Antigen ELISA kit.

Cells

PBMCs were obtained from blood buffy coats of healthy donors using Ficoll-Paque density gradient centrifugation, and then plated in 24-well, 12-well, or 6-well MULTIWELL PRIMARIA plates (Becton Dickinson, Franklin Lakes, NJ) with RPMI 1640 supplemented with 10% fetal calf serum (FCS). To obtain the monocyte population, the floating cells were removed by washing the plates with phosphate-buffered saline (PBS) four times after incubation at 37°C for 1 day. Monocytes were differentiated into macrophages for 6–11 days in the presence of 100 ng/ml of granulocyte macrophage colony stimulating factor (GM-CSF)

Figure 5. Syncytium formation in undifferentiated monocytes pretreated with HIV-2 particles and then infected with macrophage-tropic HIV-1. Monocytes were treated with VSV-G pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G) and then infected with HIV-1 strain SF162 or NL43. Presented data are representative of two independent experiments.
doi:10.1371/journal.pone.0090969.g005

(PeproTECH, Rocky Hill, NJ) or 100 ng/ml of macrophage colony stimulating factor (M-CSF) (PeproTECH).

Luciferase Assay

Macrophages ($1.6–2.4 \times 10^5$ cells) and monocytes ($2.6–3.4 \times 10^6$ cells) were pretreated for 2 h with a titer of macrophage-tropic HIV-1 strain SF162 virus equivalent to 100 ng of p24 or with a titer of GH123-Nhe/VSV-G virus equivalent to 100 ng of p27, and then infected with a titer of NL43-Luci/VSV-G virus equivalent to 7.7 ng of p24. After incubation for 2 h, the medium was changed, and cells were incubated for 4 days at 37°C. Luciferase activity was measured in cell lysates according to the manufacturer's instructions (Bright-Glo Luciferase Assay System, Promega, Madison, WI) and read using a Centro LB960 Microplate Luminometer (Berthold, Bad Wildbad, Germany).

Virus Infection

Macrophages and monocytes ($2.2–2.6 \times 10^6$ cells) were pretreated for 2 h with a titer of GH123-Nhe/VSV-G virus equivalent to 100 ng of p27, and then infected with a titer of virus equivalent to 100 ng of p24 of macrophage-tropic HIV-1 strain SF162 or laboratory-adapted T-cell line-tropic HIV-1 strain NL43. After incubation for 2 h, cells were washed with PBS and incubated with RPMI 1640 supplemented with 10% FCS and 100 ng/ml GM-CSF or 100 ng/ml M-CSF. Culture supernatants were collected periodically, and levels of HIV-1 p24 antigen were measured by the RETROtek HIV-1 p24 Antigen ELISA kit.

Western Blot

Monocytes and macrophages (3.5×10^6 cells) were lysed in Laemmli sample buffer (100 mM Tris-HCl, pH 6.8, 0.04% sodium dodecyl sulfate (SDS), 20% glycerol, 0.12% 2-mercaptoethanol). Proteins in the lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins in the gel were


Figure 6. Western blot analysis of SAMHD1 in undifferentiated monocytes and macrophages. Monocytes were differentiated into macrophages for 6 days in the presence of GM-CSF or M-CSF. Macrophages or monocytes were treated with or without VSV-G-pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G), and harvested. Whole-cell extracts were separated on SDS-PAGE and analyzed by western blot using the indicated antibodies. Presented data are representative of two independent experiments.
doi:10.1371/journal.pone.0090969.g006

Figure 7. Quantification of SAMHD1 mRNA expression. Monocytes were differentiated into macrophages for 6 days in the presence of GM-CSF or M-CSF. Macrophages or monocytes were treated with or without VSV-G-pseudotyped and Env-defective HIV-2 particles (GH123/VSV-G), and harvested. SAMHD1 mRNA expression levels were detected by real-time RT-PCR and normalized against GAPDH. Data are shown as mean ± SD.
doi:10.1371/journal.pone.0090969.g007

then electrically transferred to a membrane (Immobilion; Millipore, Billerica, MA). Blots were blocked and probed with anti-CypA affinity rabbit polyclonal antibody (Sigma, St. Louis, MO) overnight at 4°C. Blots then were incubated with peroxidase-linked protein A (GE Healthcare, Buckinghamshire, UK), and bound antibodies were visualized with a Chemilumi-One chemiluminescent kit (Nacalai Tesque, Kyoto, Japan). Quantities of cell lysate were normalized by CypA level, then subjected to a new round of SDS-PAGE and membrane transfer. For the new blot, SAMHD1 protein in the membrane was detected with anti-SAMHD1 (611–625) rabbit antibody (Sigma) followed by peroxidase-linked protein A (GE Healthcare, Buckinghamshire, UK) detection as described above.

Phosphorylation State of SAMHD1

Monocyte or macrophages (6×10^6 cells) were treated with a titer of GH123-Nhe/VSV-G virus equivalent to 500 ng of p25 for 2 h, washed with medium, and then incubated at 37°C for 4 h or 24 h. Cells were lysed in Laemmli sample buffer. Proteins in the lysates were separated by SDS-PAGE containing Phos-tag (Wako, Osaka, Japan), a ligand that decreases the mobility of phosphorylated proteins. Separated proteins in the gel were analyzed by western blotting using anti-SAMHD1 antibody. The gel images were analyzed by CS analyzer 3.0 (ATTO, Tokyo, Japan).

Quantification of SAMHD1 mRNA Expression

Total RNA was extracted from monocytes or macrophages using TRIZOL reagent (Life Technologies, Carlsbad, CA) following the manufacturer's instructions. cDNA was synthesized from 1 μg of total RNA using the High-capacity cDNA Archive kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's instructions. For real time PCR, each 20-μL reaction mixture consisted of 5 μL of cDNA, 10 μL TaqMan Universal PCR Master Mix (Applied Biosystems, Carlsbad, CA) and 1 μL of TaqMan Gene Ex Assays (Assay ID: Hs00210019_m1). Real time PCR was performed with an Applied Biosystems 7500 Real-Time PCR System. Levels of SAMHD1 mRNA were normalized with those of GAPDH according to the manufacturer's instructions.

Figure 8. Phosphorylation state of SAMHD1. Monocytes (Monocyte), M-CSF-differentiated macrophages (Macrophage (M-CSF)), and GM-CSF-differentiated macrophages (Macrophage (GM-CSF)) were treated with GH123-Nhe/VSV-G for 2 h and incubated at 37°C for 4 h (4 h) or 24 h (24 h), or mock-treated (−). Cells were lyzed and subjected for SDS-PAGE containing Phos-tag to separate phosphorylated proteins from nonphosphorylated ones. SAMHD1 proteins were detected by anti-SAMHD1 antibody. Upper bands shown by a vertical bar and a lower band shown by an arrow represent phosphorylated and nonphosphorylated SAMHD1, respectively. Ratios of phosphorylated SAMHD1 levels to total SAMHD1 levels (ratio) are shown in vertical numbers.
doi:10.1371/journal.pone.0090969.g008

RNA Interference

The cultured medium of monocytes ($1.6–2.4\times10^6$ cells) was replaced with 0.5 mL of Opti-MEM (Gibco, Carlsbad, CA) before transfection. The SAMHD1-targeting pool comprised of the siRNAs to the following target sequences: J-013950-09: 5′-GACAAUGAGUUGCGUAUUU-3′; J-013950-10: 5′-CAUGUUUGAUGGACGAUUU-3′; J-013950-11: 5′-AAGUAUUGCUAGACGUGAA-3′; J-013950-12: 5′-UUAGUUAUAUCCAGCGAUU-3′ were purchased from Dharmacon (Lafayette, CO). The GFP-targeting siRNA to the sequence 5′-GGCUACGUCCAGGAGCGCACC-3′ were used as a control siRNA. Monocytes were transfected with 40 pmol aliquots of siRNA with 2 μL of Lipofectamine 2000 (Invitrogen, Carlsbad,

A

B

Figure 9. Effects of SAMHD1 siRNA on HIV-1 infection. Monocytes (Monocyte) or macrophages (Macrophage) were treated with SAMHD1-(siSAMHD1) or GFP- (siGFP) targeting siRNAs. Three days after transfection, cells were harvested or infected with NL43-Luci/VSV-G virus. SAMHD1 mRNA expression levels in harvested cells were detected by real-time RT-PCR and normalized against GAPDH. Data are shown as mean ± SD. Luciferase activity in infected cells was measured 4 days after infection. Data are plotted as the mean ± SD of triplicate samples; presented data are representative of two independent experiments using two donors. A: Results of samples obtained from a donor 1. B: Results of samples obtained from a donor 2.
doi:10.1371/journal.pone.0090969.g009

CA) per well. Six h after transfection, cultured medium was replaced with RPMI 1640 supplemented with 10% FCS. At day 3, monocytes were infected with a titer of NL43-Luci/VSV-G virus equivalent to 7.7 ng of p24. In the case of GM-CSF-induced macrophages (1.6–3.6×10^6 cells), siRNAs were transfected at day 4 after differentiation by GM-CSF, and then infected with NL43-Luci/VSV-G virus at day 7. Total RNA was extracted from cells at the time point of NL43-Luci/VSV-G virus infection for quantification of SAMHD1 mRNA expression.

Author Contributions

Conceived and designed the experiments: EEN TS. Performed the experiments: KT EEN. Analyzed the data: KT EEN TS. Wrote the paper: KT EEN TS.

References

1. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, et al. (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47: 333–348.
2. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, et al. (1986) The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233: 215–219.
3. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, et al. (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089–1093.
4. Cheng-Mayer C, Weiss C, Seto D, Levy JA (1989) Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A 86: 8575–8579.
5. Cheng-Mayer C, Seto D, Tateno M, Levy JA (1988) Biologic features of HIV-1 that correlate with virulence in the host. Science 240: 80–82.
6. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1991) Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253: 71–74.

7. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, et al. (1990) HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348: 69–73.

8. Shioda T, Levy JA, Cheng-Mayer C (1991) Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349: 167–169.

9. Shioda T, Levy JA, Cheng-Mayer C (1992) Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89: 9434–9438.

10. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, et al. (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955–1958.

11. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, et al. (1996) A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 70: 6288–6295.

12. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135–1148.

13. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661–666.

14. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, et al. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149–1158.

15. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667–673.

16. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872–877.

17. Gorry PR, Ancuta P (2011) Coreceptors and HIV-1 pathogenesis. Curr HIV/AIDS Rep 8: 45–53.

18. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR (2007) Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J Neuroimmune Pharmacol 2: 32–41.

19. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819–822.

20. Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, et al. (2011) Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages. J Virol 85: 10699–10709.

21. Lapham CK, Zaitseva MB, Lee S, Romanstseva T, Golding H (1999) Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat Med 5: 303–308.

22. Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, et al. (2001) Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 75: 6776–6785.

23. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F (2000) Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96: 1327–1333.

24. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, et al. (2005) Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 105: 3824–3832.

25. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M (2009) A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe 6: 68–80.

26. Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, et al. (2000) Characterization of novel safe lentiviral vectors derived from simian immuno-deficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 7: 1613–1623.

27. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, et al. (2006) With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther 13: 991–994.

28. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, et al. (2008) Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol 82: 12335–12345.

29. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, et al. (2007) SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 4: 2.

30. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658–661.

31. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654–657.

32. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, et al. (2012) SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 18: 1682–1687.

33. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, et al. (2011) HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480: 379–382.

34. Kim B, Nguyen LA, Daddacha W, Hollenbaugh JA (2012) Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J Biol Chem 287: 21570–21574.

35. Bergamini A, Perno CF, Dini L, Capozzi M, Pesce CD, et al. (1994) Macrophage colony-stimulating factor enhances the susceptibility of macro-phages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding. Blood 84: 3405–3412.

36. Kedzierska K, Maerz A, Warby T, Jaworowski A, Chan H, et al. (2000) Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages. AIDS 14: 1739–1748.

37. Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, et al. (1995) Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. AIDS Res Hum Retroviruses 11: 1031–1038.

38. Pauls E, Jimenez E, Ruiz A, Permanyer M, Ballana E, et al. (2013) Restriction of HIV-1 replication in primary macrophages by IL-12 and IL-18 through the upregulation of SAMHD1. J Immunol 190: 4736–4741.

39. Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, et al. (2011) SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog 7: e1002425.

40. Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M (2013) Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep 3: 1036–1043.

41. White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen LA, et al. (2013) The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe 13: 441–451.

42. Welbourn S, Dutta SM, Semmes OJ, Strebel K (2013) Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol 87: 11516–11524.

43. Diget EA, Zuwala K, Berg RK, Laursen RR, Soby S, et al. (2013) Characterization of HIV-1 infection and innate sensing in different types of primary human monocyte-derived macrophages. Mediators Inflamm 2013: 208412.

44. Cheng-Mayer C, Rutka JT, Rosenblum ML, McHugh T, Stites DP, et al. (1987) Human immunodeficiency virus can productively infect cultured human glial cells. Proc Natl Acad Sci U S A 84: 3526–3530.

45. Ghafouri M, Amini S, Khalili K, Sawaya BE (2006) HIV-1 associated dementia: symptoms and causes. Retrovirology 3: 28.

46. Nomaguchi M, Doi N, Fujiwara S, Saito A, Akari H, et al. (2013) Systemic biological analysis of the mutations in two distinct HIV-1mt genomes occurred during replication in macaque cells. Microbes Infect 15: 319–328.